Effect of fecal microbiota transplantation on immune tonus (Not Available On-Demand)

Numerous studies have shown that the composition of the fecal microbiota is a factor impacting the response to immunotherapy-type anticancer drugs. This is particularly true during dysbiosis induced after taking antibiotics. This finding opened the door to the possibility of using gut microbiota-centered interventions to improve the likelihood of patient response to immunotherapies. One of the gut microbiota-centered therapy is fecal microbiota transplantation (FMT), already used in the treatment of certain intestinal pathologies. Understanding how FMT impacts intestinal and anti-tumor immunity is the challenge of tomorrow to improve the care of patients living with cancer. The use of the Olink Cytokine Panel in our FMT models makes it possible to highlight a variation in the immune tone of the transplant recipient.